Items where authors include "Srivastava, T."

Article

Harnan, S. orcid.org/0000-0002-9318-9206, Kearns, B. orcid.org/0000-0001-7730-668X, Scope, A. orcid.org/0000-0003-1604-1758 et al. (11 more authors) (2024) Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 28 (73). ISSN 1366-5278

Woods, B. orcid.org/0000-0002-7669-9415, Schmitt, L. orcid.org/0000-0003-1052-488X, Jankovic, D. orcid.org/0000-0002-9311-1409 et al. (10 more authors) (2024) Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 28 (28). pp. 1-238. ISSN 1366-5278

Heathcote, L. orcid.org/0000-0001-8063-7447, Srivastava, T., Sarmah, A. et al. (3 more authors) (2023) A systematic review and statistical analysis of factors influencing the cost-effectiveness of transcatheter aortic valve implantation for symptomatic severe aortic stenosis. ClinicoEconomics and Outcomes Research, 15. pp. 459-475. ISSN 1178-6981

Thokala, P. orcid.org/0000-0003-4122-2366, Srivastava, T., Smith, R. et al. (5 more authors) (2023) Living health technology assessment: issues, challenges and opportunities. PharmacoEconomics, 41 (3). pp. 227-237. ISSN 1170-7690

Srivastava, T. orcid.org/0000-0002-5961-9348, Latimer, N.R. orcid.org/0000-0001-5304-5585 and Tappenden, P. orcid.org/0000-0001-6612-2332 (2021) Estimation of transition probabilities for state-transition models : a review of NICE appraisals. PharmacoEconomics, 39 (8). pp. 869-878. ISSN 1170-7690

Rubin, G., Walter, F.M., Emery, J. et al. (10 more authors) (2021) Electronic clinical decision support tool for assessing stomach symptoms in primary care (ECASS): a feasibility study. BMJ Open, 11 (3). e041795. ISSN 2044-6055

Saiyed, M., Byrnes, J., Srivastava, T. orcid.org/0000-0002-5961-9348 et al. (2 more authors) (2020) Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clinical Drug Investigation, 40 (12). pp. 1167-1176. ISSN 1173-2563

Srivastava, T., Prabhu, V.S., Li, H. et al. (7 more authors) (2020) Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden. European Urology Oncology, 3 (5). pp. 663-670. ISSN 2588-9311

Srivastava, T. orcid.org/0000-0002-5961-9348, Strong, M. orcid.org/0000-0003-1486-8233, Stevenson, M.D. orcid.org/0000-0002-3099-9877 et al. (1 more author) (2020) Improving cycle corrections in discrete time Markov models : a Gaussian quadrature approach. medRxiv. (Submitted)

Monograph

Srivastava, T. orcid.org/0000-0002-5961-9348, Chambers, D., Thomas, C. et al. (1 more author) (2019) ECASS health economic feasibility study. Report. ScHARR HEDS Discussion Papers . School of Health and Related Research, University of Sheffield , Sheffield.

Proceedings Paper

Srivastava, T., Strong, M., Stevenson, M.D. orcid.org/0000-0002-3099-9877 et al. (1 more author) (2019) PNS337: Improving on cycle corrections for time-homogeneous markov models. In: Value in Health. ISPOR Europe 2019, 02-07 Nov 2019, Copenhagen, Denmark. Elsevier , S821-S821.